Literature DB >> 14762906

Chain length-dependent effects of alkylmaltosides on nasal absorption of enoxaparin.

Fatima Mustafa1, Tianzhi Yang, Mansoor A Khan, Fakhrul Ahsan.   

Abstract

The purpose of this study was to investigate whether the hydrophobic chain length of alkylmaltosides affects their efficacy as absorption promoters for nasally administered low-molecular-weight heparin and to study whether these agents enhance nasal absorption in a time-dependent manner without causing irreversible damage to the nasal epithelial membrane. For the nasal absorption studies, enoxaparin formulated with different alkylmaltosides was administered nasally to anesthetized rats and absorption of the drug was determined by measuring plasma anti-factor Xa activity. Reversibility studies were performed by administering enoxaparin at different time points after administration of alkylmaltosides. The AUC(0-360) for plasma anti-factor Xa-time curves increased with the increase in alkylmaltoside concentration in the formulations. Absolute and relative bioavailability of enoxaparin were increased by two-fold when the alkyl chain length of maltosides was increased from 8 to 14 carbons. Alkylmaltosides therefore increase nasal absorption of enoxaparin in a dose- and chain length-dependent manner. Of the alkylmaltosides tested, tetradecylmaltoside is the most potent enhancer of nasal absorption of enoxaparin. Longer chain alkylmaltosides produce a more prolonged effect on nasal mucosa compared with those with shorter alkyl chain. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14762906     DOI: 10.1002/jps.10579

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Inhalable lactose-based dry powder formulations of low molecular weight heparin.

Authors:  Shuhua Bai; Vivek Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

Review 2.  The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Authors:  Nusrat A Motlekar; Bi-Botti C Youan
Journal:  J Control Release       Date:  2006-06-14       Impact factor: 9.776

3.  Pulmonary delivery of low molecular weight heparins.

Authors:  Tianzhi Yang; Fatima Mustafa; Shuhua Bai; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

4.  Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium.

Authors:  Yasmine A Gomaa; Martin J Garland; Fiona McInnes; Labiba K El-Khordagui; Clive Wilson; Ryan F Donnelly
Journal:  Eur J Pharm Biopharm       Date:  2012-07-23       Impact factor: 5.571

5.  A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Authors:  Sagar Munjal; Elimor Brand-Schieber; Kent Allenby; Egilius L H Spierings; Roger K Cady; Alan M Rapoport
Journal:  J Headache Pain       Date:  2017-03-01       Impact factor: 7.277

Review 6.  Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes.

Authors:  Fahad Akhtar; Xinyu Wan; Gang Wu; Samuel Kesse; Shaoda Wang; Shuying He
Journal:  Molecules       Date:  2018-07-18       Impact factor: 4.411

7.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30

Review 8.  Nasal delivery of high molecular weight drugs.

Authors:  Yildiz Ozsoy; Sevgi Gungor; Erdal Cevher
Journal:  Molecules       Date:  2009-09-23       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.